AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24504660 — intervention group
Group type: EXPERIMENTAL
Intervention: Occlusal splints (OS)
Number of subjects: 30
Study 24504660 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 24293768 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP adherence at 1 month
Number of subjects: 275
Study 24293768 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP adherence at 6 months
Number of subjects: 275
Study 24293768 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP adherence at 12 months
Number of subjects: 275
Study 24293768 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP use at 1 month
Number of subjects: 275
Study 24293768 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP side effects at 1 month
Number of subjects: 275
Study 21379582 — intervention group
Group type: EXPERIMENTAL
Intervention: Motion discrimination with varying motion coherence and viewing time
Number of subjects: 0
Study 21379582 — intervention group
Group type: COMPARATOR
Intervention: Saccades or verbal responses for motion discrimination
Number of subjects: 0
Study 18180664 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced access to medical information (case notes from the last three visits) for intervention patients.
Number of subjects: 1799
Study 18180664 — intervention group
Group type: COMPARATOR
Intervention: Control group (no enhanced access to medical information).
Number of subjects: 1799
Study 18180664 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (n=834).
Number of subjects: 1799
Study 18180664 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=965).
Number of subjects: 1799
Study 17946466 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A (failed to maintain spontaneous breathing)
Number of subjects: 78
Study 17946466 — intervention group
Group type: COMPARATOR
Intervention: Group B (successful trials)
Number of subjects: 78
Study 17946466 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A
Number of subjects: 78
Study 17946466 — intervention group
Group type: COMPARATOR
Intervention: Group B
Number of subjects: 78
Study 15265228 — intervention group
Group type: EXPERIMENTAL
Intervention: Pram-walking exercise programme
Number of subjects: 0
Study 15265228 — intervention group
Group type: COMPARATOR
Intervention: Social support group (non-structured sessions, similar to a playgroup)
Number of subjects: 0
Study 11043991 — intervention group
Group type: EXPERIMENTAL
Intervention: Opioid analgesics
Number of subjects: 860
Study 11043991 — intervention group
Group type: COMPARATOR
Intervention: None (control group not explicitly mentioned)
Number of subjects: 860
Study 9033517 — intervention group
Group type: EXPERIMENTAL
Intervention: Mass mailing and mass media advertising campaigns
Number of subjects: 0
Study 9033517 — intervention group
Group type: COMPARATOR
Intervention: Prescreen contact
Number of subjects: 0
Study 9033517 — intervention group
Group type: COMPARATOR
Intervention: First screening visit
Number of subjects: 0
Study 8383904 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoproterenol (0.03 microgram.kg‐1.min‐1 for 60 min)
Number of subjects: 6
Study 8383904 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (1 mg.min‐1 for 5 min followed by 0.1 mg.min‐1 for 115 min)
Number of subjects: 6
Study 8383904 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol + Isoproterenol (infused between 30 and 90 min of propranolol infusion)
Number of subjects: 6
Study 8383904 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline solution)
Number of subjects: 6
Study 2946509 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific thromboxane synthetase inhibitor, UK-38,485
Number of subjects: 15
Study 2946509 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 31063434 — intervention group
Group type: EXPERIMENTAL
Intervention: Consumption of 120 g of cooked Moringa oleifera leaves
Number of subjects: 41
Study 31063434 — intervention group
Group type: COMPARATOR
Intervention: Control group (no Moringa leaves)
Number of subjects: 41
Study 29380626 — intervention group
Group type: EXPERIMENTAL
Intervention: Loss-framed messages for CVD risk reduction
Number of subjects: 217
Study 29380626 — intervention group
Group type: EXPERIMENTAL
Intervention: Gain-framed messages for psoriasis symptom reduction
Number of subjects: 217
Study 29380626 — intervention group
Group type: EXPERIMENTAL
Intervention: Loss-framed messages
Number of subjects: 217
Study 29380626 — intervention group
Group type: EXPERIMENTAL
Intervention: Gain-framed messages
Number of subjects: 217
Study 29380626 — intervention group
Group type: EXPERIMENTAL
Intervention: High CVD risk
Number of subjects: 217
Study 26576858 — intervention group
Group type: EXPERIMENTAL
Intervention: Betahistine 18 mg plus ondansetron 4 mg
Number of subjects: 168
Study 26576858 — intervention group
Group type: COMPARATOR
Intervention: Ondansetron 4 mg alone (placebo group)
Number of subjects: 168
Study 25348459 — intervention group
Group type: EXPERIMENTAL
Intervention: Male partner involvement plus a behavioral PMTCT intervention
Number of subjects: 1440
Study 25348459 — intervention group
Group type: COMPARATOR
Intervention: Control group (women attending without their male partners)
Number of subjects: 1440
Study 23285780 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketac Molar Aplicap glass-ionomer material
Number of subjects: 15
Study 23285780 — intervention group
Group type: COMPARATOR
Intervention: Control group (tooth enamel)
Number of subjects: 15
Study 20517680 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-derived growth factors (platelet-leukocyte gel)
Number of subjects: 50
Study 20517680 — intervention group
Group type: COMPARATOR
Intervention: Control (no platelet-derived growth factors)
Number of subjects: 50
Study 18528405 — intervention group
Group type: EXPERIMENTAL
Intervention: Fermented lactotripeptides (LTPs)-containing milk
Number of subjects: 0
Study 18528405 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 15882481 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based educational module promoting size acceptance
Number of subjects: 258
Study 15882481 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 258
Study 14587556 — intervention group
Group type: EXPERIMENTAL
Intervention: Large-scale ensemble averaging of ambulatory impedance cardiograms
Number of subjects: 21
Study 14587556 — intervention group
Group type: COMPARATOR
Intervention: Classical 60-sec ensemble averages
Number of subjects: 21
Study 10918098 — intervention group
Group type: EXPERIMENTAL
Intervention: Prochlorperazine (10 mg intravenously)
Number of subjects: 84
Study 10918098 — intervention group
Group type: COMPARATOR
Intervention: Promethazine (25 mg intravenously)
Number of subjects: 84
Study 9014166 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulation of the dominant eye (left or right)
Number of subjects: 26
Study 9014166 — intervention group
Group type: COMPARATOR
Intervention: Stimulation of the non-dominant eye
Number of subjects: 26
Study 1561474 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem
Number of subjects: 45
Study 1561474 — intervention group
Group type: COMPARATOR
Intervention: Nitroglycerin
Number of subjects: 45
Study 1561474 — intervention group
Group type: EXPERIMENTAL
Intervention: Both drugs
Number of subjects: 45
Study 3886303 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg tiaprofenic acid 3-times daily
Number of subjects: 11
Study 3886303 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 30527259 — intervention group
Group type: EXPERIMENTAL
Intervention: Cottonseed oil (CSO) diet
Number of subjects: 15
Study 30527259 — intervention group
Group type: COMPARATOR
Intervention: Olive oil (OO) diet
Number of subjects: 15
Study 26250967 — intervention group
Group type: EXPERIMENTAL
Intervention: Early egg introduction
Number of subjects: 40
Study 26250967 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 24628859 — intervention group
Group type: COMPARATOR
Intervention: Patients reporting no angina symptoms (n=28)
Number of subjects: 548
Study 24628859 — intervention group
Group type: COMPARATOR
Intervention: Patients reporting monthly angina (n=188)
Number of subjects: 548
Study 24628859 — intervention group
Group type: COMPARATOR
Intervention: Patients reporting weekly angina (n=283)
Number of subjects: 548
Study 24628859 — intervention group
Group type: COMPARATOR
Intervention: Patients reporting daily angina (n=49)
Number of subjects: 548
Study 24628859 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients improving ≥1 SAQAF classification (n=254/541, 47%)
Number of subjects: 548
Study 24628859 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients improving ≥20 points on the SAQAF (n=355/541, 66%)
Number of subjects: 548
Study 22458918 — intervention group
Group type: EXPERIMENTAL
Intervention: Brimonidine 0.2%-timolol 0.5%
Number of subjects: 148
Study 22458918 — intervention group
Group type: COMPARATOR
Intervention: Latanoprost 0.005%
Number of subjects: 148
Study 20035174 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive medial plating using hybrid locking and nonlocking techniques
Number of subjects: 38
Study 20035174 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 38
Study 17881928 — intervention group
Group type: EXPERIMENTAL
Intervention: Prethickened formula (AR)
Number of subjects: 74
Study 17881928 — intervention group
Group type: COMPARATOR
Intervention: Regular formula (R)
Number of subjects: 74
Study 15901241 — intervention group
Group type: EXPERIMENTAL
Intervention: Ischaemic preconditioning (IP)
Number of subjects: 36
Study 15901241 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicorandil (an agonist of KATP channels)
Number of subjects: 36
Study 15901241 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 36
Study 15901241 — intervention group
Group type: EXPERIMENTAL
Intervention: IP pretreated with glibenclamide (an antagonist of KATP channels)
Number of subjects: 36
Study 12020982 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene 60 mg/day
Number of subjects: 36
Study 12020982 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 9882035 — intervention group
Group type: EXPERIMENTAL
Intervention: Leeds Dyspepsia Questionnaire (LDQ) administered to patients with dyspepsia
Number of subjects: 314
Study 9882035 — intervention group
Group type: EXPERIMENTAL
Intervention: Leeds Dyspepsia Questionnaire (LDQ) for test-retest reliability
Number of subjects: 314
Study 9882035 — intervention group
Group type: EXPERIMENTAL
Intervention: Leeds Dyspepsia Questionnaire (LDQ) for inter-rater reliability
Number of subjects: 314
Study 9882035 — intervention group
Group type: EXPERIMENTAL
Intervention: Leeds Dyspepsia Questionnaire (LDQ) before and after therapy
Number of subjects: 314
Study 7927617 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatitis B vaccine (Engerix B-10 microgram each) at 0, 6 and 14 weeks (group A)
Number of subjects: 39
Study 7927617 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatitis B vaccine (Engerix B-10 microgram each) at 0, 1 and 2 months (group B)
Number of subjects: 39
Study 3286327 — intervention group
Group type: EXPERIMENTAL
Intervention: Human proinsulin (HPI)
Number of subjects: 114
Study 3286327 — intervention group
Group type: COMPARATOR
Intervention: rDNA human insulin (HI)
Number of subjects: 114
Study 29077864 — intervention group
Group type: EXPERIMENTAL
Intervention: Sofosbuvir + Grazoprevir/Elbasvir + Ribavirin for 16 weeks
Number of subjects: 26
Study 29077864 — intervention group
Group type: EXPERIMENTAL
Intervention: Sofosbuvir + Grazoprevir/Elbasvir + Ribavirin for 24 weeks
Number of subjects: 26
Study 27098193 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation (2800 IU)
Number of subjects: 200
Study 27098193 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study 24958656 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic-training (AT)
Number of subjects: 46
Study 24958656 — intervention group
Group type: COMPARATOR
Intervention: Strength-training (ST)
Number of subjects: 46
Study 24228531 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional Chinese medicine combined HAART
Number of subjects: 37
Study 24228531 — intervention group
Group type: COMPARATOR
Intervention: HAART
Number of subjects: 37
Study 21642064 — intervention group
Group type: EXPERIMENTAL
Intervention: Robot-assisted gait training (RAGT) combined with conventional physical therapy (24 1-hour sessions)
Number of subjects: 20
Study 21642064 — intervention group
Group type: COMPARATOR
Intervention: Conventional physical therapy (24 1-hour sessions)
Number of subjects: 20
Study 19564366 — intervention group
Group type: EXPERIMENTAL
Intervention: Artemether-lumefantrine (80/480 mg) twice daily for 3 days
Number of subjects: 103
Study 19564366 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictive modeling suggests a twice-daily regimen for 5 days would be preferable in later pregnancy
Number of subjects: 103
Study 17058041 — intervention group
Group type: EXPERIMENTAL
Intervention: High TMS stimulation
Number of subjects: 42
Study 17058041 — intervention group
Group type: EXPERIMENTAL
Intervention: Low TMS stimulation
Number of subjects: 42
Study 15318468 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin 5 mg
Number of subjects: 66
Study 15318468 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam 15 mg
Number of subjects: 66
Study 15318468 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study 11511127 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive averaging task with varying liquid volumes (Experiment 1)
Number of subjects: 0
Study 11511127 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive averaging task with varying liquid volumes (Experiment 2)
Number of subjects: 0
Study 11229183 — intervention group
Group type: EXPERIMENTAL
Intervention: Early haemodialysis (Group B)
Number of subjects: 35
Study 11229183 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment (Group A)
Number of subjects: 35
Study 8280547 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. pethidine
Number of subjects: 20
Study 8280547 — intervention group
Group type: EXPERIMENTAL
Intervention: rectal pethidine
Number of subjects: 20
Study 6695297 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg diazoxide
Number of subjects: 0
Study 6695297 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg diazoxide
Number of subjects: 0
Study 6695297 — intervention group
Group type: COMPARATOR
Intervention: 300 mg diazoxide
Number of subjects: 0
Study 31121104 — intervention group
Group type: EXPERIMENTAL
Intervention: Cx601 (darvadstrocel)
Number of subjects: 0
Study 31121104 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatments
Number of subjects: 0
Study 30409170 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily mobilisation in a tilt table with an integrated stepping device (ERIGO)
Number of subjects: 60
Study 30409170 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 60
Study 26248565 — intervention group
Group type: EXPERIMENTAL
Intervention: Dairy supplementation
Number of subjects: 26
Study 26248565 — intervention group
Group type: EXPERIMENTAL
Intervention: Nondairy isocaloric and isoprotein supplement
Number of subjects: 26
Study 26248565 — intervention group
Group type: COMPARATOR
Intervention: Control group (no supplementation)
Number of subjects: 26
Study 25440373 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 19
Study 25440373 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture plus stretching
Number of subjects: 19
Study 25440373 — intervention group
Group type: COMPARATOR
Intervention: Placebo laser acupuncture
Number of subjects: 19
Study 22878686 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25% bupivacaine (Group B)
Number of subjects: 124
Study 22878686 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.20% ropivacaine (Group R)
Number of subjects: 124
Study 22878686 — intervention group
Group type: COMPARATOR
Intervention: No injection (Group C)
Number of subjects: 124
Study 20728318 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole 15 mg/day
Number of subjects: 401
Study 20728318 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole 30 mg/day
Number of subjects: 401
Study 20728318 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 401
Study 17663105 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture treatment group
Number of subjects: 68
Study 17663105 — intervention group
Group type: COMPARATOR
Intervention: Control group (anti-infection, inhibiting secretion of pancreas, improving microcirculation, protective agent of gastric mucosa)
Number of subjects: 68
Study 17663105 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 68
Study 17288334 — intervention group
Group type: COMPARATOR
Intervention: RelyX ARC-Single Bond (Group I C)
Number of subjects: 100
Study 17288334 — intervention group
Group type: COMPARATOR
Intervention: Duo Link-One Step (Group II C)
Number of subjects: 100
Study 17288334 — intervention group
Group type: EXPERIMENTAL
Intervention: RelyX Temp NE (Groups I ND and II ND)
Number of subjects: 100
Study 17288334 — intervention group
Group type: EXPERIMENTAL
Intervention: RelyX Temp E (Groups I ED and II ED)
Number of subjects: 100
Study 17288334 — intervention group
Group type: EXPERIMENTAL
Intervention: RelyX NE (Groups I N and II N)
Number of subjects: 100
Study 17288334 — intervention group
Group type: EXPERIMENTAL
Intervention: RelyX E (Groups I E and II E)
Number of subjects: 100
Study 17288334 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual bonding technique (Groups I ND and ED, II ND and ED)
Number of subjects: 100
Study 15229064 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 22
Study 15229064 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 11155965 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective serotonin reuptake inhibitors (SSRIs)
Number of subjects: 0
Study 11155965 — intervention group
Group type: COMPARATOR
Intervention: Tricyclic antidepressants (TCAs)
Number of subjects: 0
Study 11155965 — intervention group
Group type: EXPERIMENTAL
Intervention: TCAs plus lithium, monoamine oxidase inhibitors (MAOIs), or electroconvulsive therapy (ECT)
Number of subjects: 0
Study 8923355 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human tumor necrosis factor receptor (p80) fusion protein (rhTNFR:Fc)
Number of subjects: 22
Study 8923355 — intervention group
Group type: COMPARATOR
Intervention: Placebo injection
Number of subjects: 22
Study 1455983 — intervention group
Group type: EXPERIMENTAL
Intervention: Mexiletine (MXT)
Number of subjects: 30
Study 1455983 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocainide (TCD)
Number of subjects: 30
Study 1455983 — intervention group
Group type: COMPARATOR
Intervention: Disopyramide
Number of subjects: 30
Study 1455983 — intervention group
Group type: COMPARATOR
Intervention: Phenytoin
Number of subjects: 30
Study 1455983 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 30
Study 6697306 — intervention group
Group type: EXPERIMENTAL
Intervention: Regimen 2 (modified LSA2-L2)
Number of subjects: 256
Study 6697306 — intervention group
Group type: COMPARATOR
Intervention: Regimen 1 (COMP: modified cyclophosphamide, Oncorin, methotrexate, prednisone)
Number of subjects: 256
Study 6697306 — intervention group
Group type: COMPARATOR
Intervention: Regimen 1 (COMP)
Number of subjects: 256
Study 30942014 — intervention group
Group type: EXPERIMENTAL
Intervention: Chicken‐claw needling at Shangbaxie (Extra) and Hegu (LI 4) combined with acupuncture at Houxi (SI 3)
Number of subjects: 42
Study 30942014 — intervention group
Group type: COMPARATOR
Intervention: Conventional acupuncture at the same points as the observation group
Number of subjects: 42
Study 28664388 — intervention group
Group type: EXPERIMENTAL
Intervention: Photobiomodulation therapy (PBM) from admission (AD) to D+7
Number of subjects: 51
Study 28664388 — intervention group
Group type: COMPARATOR
Intervention: Control group (oral hygiene)
Number of subjects: 51
Study 28664388 — intervention group
Group type: EXPERIMENTAL
Intervention: Photobiomodulation therapy (PBM)
Number of subjects: 51
Study 28664388 — intervention group
Group type: COMPARATOR
Intervention: Both groups (PBM and control)
Number of subjects: 51
Study 26713987 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal mask
Number of subjects: 118
Study 26713987 — intervention group
Group type: COMPARATOR
Intervention: Nasal prongs
Number of subjects: 118
Study 23167783 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromocriptine 2.5 mg daily for 14 days
Number of subjects: 28
Study 23167783 — intervention group
Group type: COMPARATOR
Intervention: Folic acid 2.0 mg daily for 14 days (Control)
Number of subjects: 28
Study 21663423 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 20
Study 21663423 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 19184217 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine-soaked Tabotamp positioned in the gallbladder bed
Number of subjects: 45
Study 19184217 — intervention group
Group type: EXPERIMENTAL
Intervention: bupivacaine infiltrated in the muscular fasciae of the trocars' seat
Number of subjects: 45
Study 19184217 — intervention group
Group type: COMPARATOR
Intervention: Control group (not using local anesthetic)
Number of subjects: 45
Study 16393430 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivastigmine
Number of subjects: 994
Study 16393430 — intervention group
Group type: COMPARATOR
Intervention: Donepezil
Number of subjects: 994
Study 16393430 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivastigmine and Donepezil
Number of subjects: 994
Study 14510929 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate (50 mg daily after titration)
Number of subjects: 0
Study 14510929 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 10732883 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril
Number of subjects: 159
Study 10732883 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 159
Study 8884144 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG Pasteur
Number of subjects: 106
Study 8884144 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG RIV
Number of subjects: 106
Study 8884144 — intervention group
Group type: COMPARATOR
Intervention: No adjuvant treatment
Number of subjects: 106
Study 8884144 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG-treated patients (both types)
Number of subjects: 106